Lightspeed is a topic tracked in our intelligence system with 6 linked articles.
OpenAI researcher Miles Wang is in talks to launch an AI-driven drug-discovery startup valued at about $2B with ~$200M in funding discussions led by Lightspeed, amid a growing cluster of AI-biotech funding and a high-stakes Apple trade-secrets lawsuit against OpenAI that elevates regulatory and IP risk for such ventures.
New York State enacted an executive order halting permits for new data centers 50 MW and larger, pending environmental review, with a potential one-year moratorium and additional legislative moves targeting 20 MW+ projects.
OpenAI’s GPT-5.6 Sol reportedly deletes files per a safety system card, Apple sues OpenAI for trade secrets with multiple former Apple employees implicated, and Miles Wang’s move to found a $2B AI drug-discovery startup highlights substantial capital and regulatory/competitive activity around AI hardware and biotech.
Google Images gets a Pinterest-like, discovery-focused redesign with a 'For You' gallery and real-time updates, plus in-Search AI image generation, while the piece also flags regulatory risk and funding signals in AI for life sciences.
AI funding, regulatory risk, and product-detail signals surface across Suno’s funding/litigation, Gemini 3's limitations, Google’s Nano Banana Pro pricing/features, India’s scam-protection push, and TikTok’s AI-content labeling initiatives.
Triomics raises a $22M Series B led by Battery Ventures to scale its oncology-specialized AI platform, targeting data-heavy clinical workflows and regulatory reporting, with strong early clinical adoption and rapid ARR/customer growth.
Subscribe for real-time topic updates and unlimited access to our intelligence platform.